Although studies specifically targeting c-MET inhibition in HNSCC are limited, preclinical research suggests that the c-MET/HGF pathway could provide therapeutic benefits by modulating tumor progression and metastasis.83 Two clinical trials have evaluated MET inhibitors in combination with ICIs, but both primarily focus on NSCLC rather than HNSCC (NCT04139317, NCT03911193). Here, MET is linked to non-small cell lung carcinoma.